| Main Title |
Economic impact and regulatory flexibility analysis of proposed effluent guidelines for the pharmaceutical manufacturing industry : final report. |
| CORP Author |
Environmental Protection Agency, Washington, DC. Engineering and Analysis Div. |
| Publisher |
U.S. Environmental Protection Agency, Office of Water, Office of Science and Technology, Engineering and Analysis Division, |
| Year Published |
1995 |
| Report Number |
EPA 821-R-95-018 |
| Stock Number |
PB95-219010 |
| OCLC Number |
32655298 |
| Subjects |
Effluent quality--Standards--Compliance costs ;
Pharmaceutical industry--Environmental aspects--United States ;
Pharmaceutical industry--United States--Environmental aspects
|
| Additional Subjects |
Drug industry ;
Water pollution control ;
Economic impact ;
Waste water treatment ;
Industrial waste treatment ;
Facilities management ;
Operation and maintenance ;
Chemical effluents ;
Water pollution standards ;
Standards compliance ;
Pollution regulations ;
Requirements ;
Water pollution economics ;
Cost analysis ;
Employment ;
Prices ;
Profits ;
Closures ;
Small businesses ;
Economic analysis ;
Market analysis ;
Pharmaceutical manufacturing ;
Regulatory Flexibility Act
|
| Internet Access |
|
| Holdings |
| Library |
Call Number |
Additional Info |
Location |
Last
Modified |
Checkout
Status |
| EJAD |
EPA 821/R-95-018 |
|
Region 3 Library/Philadelphia, PA |
07/21/1995 |
| EJED |
EPA 821-R-95-018 |
|
OCSPP Chemical Library/Washington,DC |
12/31/1998 |
| ELBD ARCHIVE |
EPA 821-R-95-018 |
Received from HQ |
AWBERC Library/Cincinnati,OH |
10/04/2023 |
| ELBD |
EPA 821-R-95-018 |
|
AWBERC Library/Cincinnati,OH |
01/24/2017 |
| NTIS |
PB95-219010 |
Some EPA libraries have a fiche copy filed under the call number shown. |
|
07/26/2022 |
|
| Collation |
1 volume (various pagings) : illustrations ; 28 cm |
| Abstract |
The economic impact analysis (EIA) examines compliance costs and economic impacts resulting from the U.S. Environmental Protection Agency's (EPA's) proposed revisions to effluent guidelines for the U.S. pharmaceutical industry. The EIA estimates the economic effects of compliance with the proposed regulation in terms of annualized costs; facility closures; changes in rate of return on assets and the interest coverage ratio at the firm level; and profitability effects at the firm level. In addition, impacts on employment and affected communities, foreign trade, specific demographic groups, and new sources also are considered. Finally, a Regulatory Flexibility Analysis detailing the impacts on small businesses within the pharmaceutical industry is included in the EIA. |
| Notes |
"February 1995." Includes bibliographical references. "EPA 821-R-95-018"--Cover. |
